Page last updated: 2024-08-16
sb 202190 and l 365260
sb 202190 has been researched along with l 365260 in 1 studies
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Bergé, G; Carnazzi, E; Gagne, D; Galleyrand, JC; Ibarz, G; Martinez, J; Morel, C; Oiry, C | 1 |
Other Studies
1 other study(ies) available for sb 202190 and l 365260
| Article | Year |
|---|---|
Cross-interactions of two p38 mitogen-activated protein (MAP) kinase inhibitors and two cholecystokinin (CCK) receptor antagonists with the CCK1 receptor and p38 MAP kinase.
Topics: Adenosine Triphosphate; Animals; Benzodiazepinones; Binding Sites; Blotting, Western; COS Cells; Devazepide; Dose-Response Relationship, Drug; Enzyme Inhibitors; Genes, Reporter; Hormone Antagonists; Imidazoles; Immunoblotting; Inositol Phosphates; Kinetics; Ligands; MAP Kinase Signaling System; Models, Chemical; Models, Molecular; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Protein Binding; Protein Conformation; Pyridines; Rats; Receptor, Cholecystokinin A; Receptors, Cholecystokinin; Signal Transduction; Time Factors; Transfection | 2005 |